A literature review published in Open Heart (2015;2(1):e000326. doi:10.1136/openhrt-2015-000326) examined the potential role of coenzyme Q10 (CoQ10) supplementation in patients with heart failure. CoQ10 is a key component of mitochondrial electron transport and is essential for cellular energy production. It is synthesized by all cells and also functions as a lipid-soluble antioxidant, helping protect cell membranes from oxidative damage.
Patients with congestive heart failure have consistently been found to have lower circulating and myocardial levels of CoQ10, with levels declining as disease severity increases. This observation has prompted interest in whether restoring CoQ10 levels may influence cardiac function and clinical outcomes.
Multiple clinical studies have reported improvements in cardiac performance with CoQ10 supplementation. The largest and most rigorous of these is the multicenter, randomized, placebo-controlled Q-SYMBIO trial, which began in 2003 and evaluated CoQ10 supplementation in patients with chronic heart failure.
In this trial, patients receiving CoQ10 experienced a 43% reduction in cardiovascular mortality compared with the placebo group. Serious adverse cardiac events—defined as major adverse cardiovascular events (MACE)—occurred in 15% of patients in the CoQ10 group versus 26% in the placebo group, representing a statistically significant 43% relative reduction.
Supplementation with CoQ10 was also associated with a 42% reduction in all-cause mortality. Unplanned hospitalizations were less frequent in the CoQ10 group (8%) compared with the placebo group (14%). Functional status improved as well: 58% of CoQ10-treated patients improved by at least one New York Heart Association (NYHA) functional class, compared with 45% in the placebo group. Notably, one participant receiving CoQ10 improved from NYHA class IV to class I during the study period.
Taken together, these findings suggest that CoQ10 supplementation may be linked with meaningful improvements in survival, hospitalization rates, and functional capacity in patients with heart failure. While these results are compelling, the authors emphasized that CoQ10 should be viewed as an adjunct to standard care rather than a replacement, and that continued research is warranted.
